Chris Hill
Analyst · Evercore ISI. Please go ahead
Thanks, Larry. I would like to begin by highlighting a couple of announcements we made since our last call. As you may be aware, the company shares were previously dual listed on the New York Stock Exchange and the Euronext Amsterdam Exchange. However, as we rationalize benefits versus the cost of maintaining the dual listing, we decided to de-list the shares from the Amsterdam Exchange, which became effective in early December of last year. In following the de-listing of the shares on January 17 of this year, we announced our plan to reorganize the company's corporate structure which includes redomesticating the parent company from the Netherlands to the United States. The company and its Board believes the redomestication will enhance long-term shareholder value by reducing administrative costs, simplifying the corporate structure, as well as gaining some operational efficiencies. The company filed a preliminary prospectus and proxy statement associated with the redomestication, which will require shareholder approval. We anticipate the redomestication transaction will be completed sometime in the first half of this year. Before we review the financial performance for the quarter, the guidance we gave on our last call and past calls specifically excluded the impact of any FX gains or losses and assumed an effective tax rate of 20%. So accordingly, our discussion today excludes any foreign exchange gain or loss for current and prior periods. Additionally, the GAAP financial results for the fourth quarter include a non-cash adjustment of $1.9 million, which decreased stock compensation expense associated with performance share awards, which vested during the quarter. This adjustment has also been excluded from the discussion of our fourth quarter and full-year results. Now looking at the income statement, revenue from continuing operations was $127.6 million in the fourth quarter, up slightly from $126 million in the prior quarter. The sequential increase in revenue was driven by growth in both the U.S. and international markets. However, nice growth in multiple international regions has been partially offset by continued disruptions caused by the ongoing Russia-Ukraine conflict, which adversely impacted service revenue in the affected regions. Of this revenue, service revenue, which is more international, was $88.9 million for the quarter up from $87.9 million last quarter. During the quarter, we saw nice sequential growth of 11% in the U.S., which was led by our laboratory services and well diagnostic services. We also see nice sequential improvement in multiple international regions outside the areas impacted by the Russia-Ukraine conflict. However, the Russia-Ukraine conflict has continued to disrupt the trading patterns and flow of oil in the affected regions. The realignment of these trading patterns still continues, and the realignment of these trading patterns has not been consistent or linear. For example, in Europe, our crude oil assay activity increased during the third quarter, but activity decreased again in the fourth quarter. The company believes these trading patterns will become more stable throughout 2023, and we will continue to monitor the changes to the trading patterns and appropriately adopt -- adapt our operations accordingly. For the full-year of 2022, service revenue of $347 million was relatively flat compared to $344.3 million in 2021. As Larry mentioned, two main factors have adversely impacted our international revenue by over $20 million in 2022. The devaluation of certain currencies, primarily the Euro and British pound; and disruptions caused by the Russia-Ukraine conflict as we just discussed. Product sales, which is equally tied to North America and international activity were $38.6 million for the quarter, up slightly compared to $38.1 million last quarter. International product sales for the quarter were up 15% sequentially, and our energetic sales to the U.S. market were also up sequentially. However, this growth was partially offset by a decrease of approximately $2 million in other product sales. For the full-year of 2022, product sales revenue was of $142.8 million was up 13% from $125.9 million in 2021. Moving on to the cost of services ex-items for the quarter are 78% of service revenue, which is comparable to last quarter. The service side of our business has been more impacted by the Russia-Ukraine conflict, although we see improvements in absorption of costs and nice incremental margins in regions where activity is expanding these gains are being offset by disruption to the business in other regions more directly impacted by the conflict. Cost of sales ex-items in the fourth quarter were 79% of revenue and improved from 82% last quarter. The improvement this quarter was primarily driven by gains in manufacturing efficiencies and higher international sales. Manufacturing costs continue to increase due to inflation on materials and other operating costs. However, some of the impact has been mitigated through gains in manufacturing efficiencies and some improvement in pricing. G&A ex-items for the quarter was $10.4 million, relatively flat compared to last quarter. For the full-year of 2022, G&A ex-items was $39.3 million, up from $37 million in 2021 due to restoration of employee compensation and benefits. For 2023, we expect G&A to be approximately $40 million to $42 million. Depreciation and amortization for the quarter was $4.1 million and comparable to last quarter. For the full-year depreciation and amortization expense was $17.2 million, down from $18.5 million in 2021. EBIT ex-items for the quarter was $14.7 million, up 10% from $13.3 million last quarter, and representing an EBIT margin of approximately 12%, which is also up from 11% last quarter. Operating income for the fourth quarter on a GAAP basis was $15.6 million. And for the full-year of 2022, EBIT ex-items was $44.8 million, down from $52.3 million in the prior year and on a GAAP basis, EBIT was $41.5 million for 2022 and $45.3 million in 2021. Interest expense was $3.1 million in comparable to last quarter and interest expense ex-items for the full-year was $11.4 million, up slightly from $11 million in 2021. Although, interest rates have significantly increased throughout 2022 the company has substantially offset the impact of this increase by reducing our outstanding debt. On a GAAP basis, interest expense for the full-year of 2022 was $11.6 million, up from $9.2 million in 2021, as 2021 interest expense included a $1.4 million gain associated with settling some of our interest rate hedges last year. Income tax expense ex-items and using an effective tax rate of 20% for the quarter was $2.3 million. On a GAAP basis, the company recorded income tax expense of $5.8 million for the quarter. And for the full-year, income tax expense was $10.3 million, resulting in an effective tax rate of 34% for 2022. However, income tax expense was significantly increased in 2022 due to the devaluation of foreign currencies, primarily Turkey and the United Kingdom, which we discussed in prior quarters. Excluding the impact associated with the devaluation of the Turkish lira and British pound, the company's effective tax rate would've been approximately 18%. The effective tax rate will continue to be somewhat sensitive to the geographic mix of earnings across the globe and the impact of items discrete to each quarter. However, we continue to project the company's effective tax rate to be approximately 20%. Income from continuing operations ex-items for the quarter was $9.3 million, up 11% sequentially from $8.3 million last quarter. For the full-year 2022 ex-items, it was $26.8 million, down from $33 million in 2021. GAAP income from continuing operations for the quarter was $6.7 million, and for the full-year 2022 was $19.7 million. Earnings per diluted share from continuing operations ex-items was $0.20 for the quarter, up from $0.18 last quarter, and was $0.57 for the full-year of 2022. GAAP earnings per diluted share from continuing operations was $0.14 for the quarter and $0.42 for the full-year. Now moving on to the balance sheet, receivables were $106.9 million at December 31, up $6.7 million from last quarter end. Our DSOs for the fourth quarter were at 70 days also up when compared to 67 days last quarter. The increase was primarily driven by the timing of billings during the quarter and a slightly higher mix of international revenue, which generally has a longer collection period. Inventory finished the year at $60.4 million, up approximately $5.6 million from last quarter end. Inventory turns for the quarter were at 2.1 down from 2.3 in the last quarter, and primarily down due to shipping delays postponing some larger international sales into 2023. As previously highlighted, the company continues to experience an increase in cost of raw materials, labor, packaging, and transportation costs, which are increasing the cost of inventory. Additionally, challenges in the supply chain persist, which will continue to require carrying a larger amount of inventory to help mitigate disruptions. We anticipate inventory turns will remain at similar levels, but we have a focused effort for improvement as we progress into 2023. On the liability side of the balance sheet, our long-term debt was $175 million at December 31 and was reduced by $10 million this quarter. Our debt is currently comprised of our senior notes at $135 million as well as $40 million outstanding under our bank revolving credit facility. As Larry mentioned earlier, our free cash flow has also improved as the company's financial performance has improved the last couple of quarters. Our free cash flow continues to be focused on reducing outstanding debt, considering cash of $15.4 million, our net debt was $159.6 million at year-end, a reduction of $11.7 million this quarter, which also improved our leverage ratio to 2.29 from 2.42 at last quarter end. Since announcing the company's commitment and focus on reducing debt in the fourth quarter of 2019, we have reduced net debt by 46%. The company will continue applying free cash towards reducing debt, so that company reaches its target leverage ratio of 1.5 or lower. Looking at cash flow for the fourth quarter of 2022, cash flow from operating activities was $13.2 million, and after paying for $2 million of CapEx, our free cash flow was $11.2 million for the quarter. Our free cash flow generated this quarter is the highest we have achieved since the third quarter of 2020. Looking forward to 2023, we expect CapEx to modestly expand and will continue to remain in line with historical levels, but also be aligned with activity levels. For the full-year of 2023, we expect capital expenditures to be in the range of $12 million to $15 million, which is an increase from $10.2 million in 2022. Core will continue our strict capital discipline and asset-like business model with capital expenditures primarily targeted at growth opportunities and initiatives. Core Lab's operational leverage continues to provide for the ability to grow revenue and profitability with minimal capital requirements. Capital expenditures have historically ranged from 2.5% to 4% of revenue even during periods of significant growth. That same level of laboratory infrastructure, intellectual property, and leverage exists in the business today. We believe evaluating a company's ability to generate free cash flow and free cash flow yield is an important metric for shareholders when comparing and projecting company's financial results, particularly for those shareholders who utilize discounted cash flow models to assess valuations. I will now turn it over to Gwen for an update on our guidance and outlook.